nach oben

International Urology and Nephrology

Erschienen in:

03.02.2016 | Urology - Review

Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?

verfasst von: Senol Tonyali, Sertac Yazici

Erschienen in: International Urology and Nephrology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

The role of metastasectomy on survival in advanced/urologic malignancies still remains unclear. Renal cell carcinoma (RCC) is the most common solid tumor within the kidney. 25–30 % of patients have metastases at manifestation. Urothelial carcinoma (UC) consists of bladder carcinoma, upper urinary tract urothelial cell carcinoma and urethral carcinoma. Bladder cancer is the ninth most common cancer worldwide. Half of patients with muscle invasive bladder cancer have lymph node or distant metastases. In metastatic disease first-line treatment is multi-agent platinum-based systemic chemotherapy. Testicular cancer is the most common cancer in men between the age of 15 and 35. Testicular tumors represent excellent oncologic outcomes. Prostate cancer is the most common solid tumor in Europe. Surgical resection of metastases can be considered as a treatment choice in advanced/metastatic urologic malignancies to improve survival rates, particularly in RCC and UC. Metastasectomy can be suggested in conjunction with effective chemotherapy if complete resection is possible. Solitary metastasectomy can represent better survival rates compared to multiple metastasectomy even if multiple metastases confined to single organ. Site of metastases is one of the main determinants of successful metastasectomy such as lung metastasectomy in urothelial cell carcinoma and liver metastasectomy in RCC may lead to better oncologic outcomes. Due to the lack of the relevant data it is not possible to make an evidence-based recommendation on the role of metastasectomy for solitary-/organ-confined metastases of prostate cancer, testicular cancer and penile cancer.

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924. doi:10.1016/j.eururo.2015.01.005 CrossRefPubMed

Swanson DA (2004) Surgery for metastases of renal cell carcinoma. Scand J Surg 93(2):150–155PubMed

Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23(4):832–841. doi:10.1200/JCO.2005.05.179 CrossRefPubMed

Tanis PJ, van der Gaag NA, Busch OR, van Gulik TM, Gouma DJ (2009) Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Brit J Surg 96(6):579–592. doi:10.1002/bjs.6606 CrossRefPubMed

Thyavihally YB, Mahantshetty U, Chamarajanagar RS, Raibhattanavar SG, Tongaonkar HB (2005) Management of renal cell carcinoma with solitary metastasis. World J Surg Oncol 3:48. doi:10.1186/1477-7819-3-48 CrossRefPubMedPubMedCentral

Pomer S, Klopp M, Steiner HH, Brkovic D, Staehler G, Cabillin-Engenhart R (1997) Brain metastases in renal cell carcinoma. Results of treatment and prognosis. Der Urologe Ausg A 36(2):117–125CrossRefPubMed

Martinez Ruiz J, Ruiz Mondejar R, Carrion Lopez P, Martinez Sanchiz C, Donate Moreno MJ, Pastor Navarro H, Peran Teruel M, Virseda Rodriguez JA (2011) Vaginal metastasis of a clear renal cell carcinoma. Arch Esp Urol 64(4):380–383PubMed

Matsumoto K, Hayakawa N, Nakamura S, Oya M (2015) Bladder metastasis from renal cell carcinoma: retrospective analysis of 65 reported cases. Clin Exp Metastasis 32(2):135–141. doi:10.1007/s10585-015-9698-1 CrossRefPubMed

Tolia BM, Whitmore WF Jr (1975) Solitary metastasis from renal cell carcinoma. J Urol 114(6):836–838PubMed

10.

Kozlowski JM (1994) Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urol Clin N Am 21(4):601–624

11.

van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM (1999) Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 35(3):197–203CrossRefPubMed

12.

Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, Karl A, Stief CG, Jauch KW, Bruns CJ (2010) Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol 28(4):543–547. doi:10.1007/s00345-010-0560-4 CrossRefPubMed

13.

Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48 (1):77–81; discussion 81–72. doi:10.1016/j.eururo.2005.03.004

14.

Hatzaras I, Gleisner AL, Pulitano C, Sandroussi C, Hirose K, Hyder O, Wolfgang CL, Aldrighetti L, Crawford M, Choti MA, Pawlik TM (2012) A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB 14(8):532–538. doi:10.1111/j.1477-2574.2012.00495.x CrossRefPubMedPubMedCentral

15.

Antonelli A, Arrighi N, Corti S, Legramanti S, Zanotelli T, Cozzoli A, Cunico SC, Simeone C (2012) Surgical treatment of atypical metastasis from renal cell carcinoma (RCC). BJU Int 110(11 Pt B):E559–E563. doi:10.1111/j.1464-410X.2012.11271.x CrossRefPubMed

16.

Baloch KG, Grimer RJ, Carter SR, Tillman RM (2000) Radical surgery for the solitary bony metastasis from renal-cell carcinoma. J Bone Joint Surg Brit 82(1):62–67CrossRefPubMed

17.

Sellner F, Tykalsky N, De Santis M, Pont J, Klimpfinger M (2006) Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: an indication for pancreatic surgery. Ann Surg Oncol 13(1):75–85. doi:10.1245/ASO.2006.03.064 CrossRefPubMed

18.

Sohn TA, Yeo CJ, Cameron JL, Nakeeb A, Lillemoe KD (2001) Renal cell carcinoma metastatic to the pancreas: results of surgical management. J Gastrointest Surg 5(4):346–351CrossRefPubMed

19.

Benhaim R, Oussoultzoglou E, Saeedi Y, Mouracade P, Bachellier P, Lang H (2015) Pancreatic metastasis from clear cell renal cell carcinoma: outcome of an aggressive approach. Urology 85(1):135–140. doi:10.1016/j.urology.2014.09.034 CrossRefPubMed

20.

Kim DY, Karam JA, Wood CG (2014) Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol 32(3):631–642. doi:10.1007/s00345-014-1293-6 CrossRefPubMed

21.

Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM (2011) Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439–444. doi:10.1016/j.juro.2010.09.086 CrossRefPubMedPubMedCentral

22.

Ljungberg B (2013) The role of metastasectomy in renal cell carcinoma in the era of targeted therapy. Curr Urol Rep 14(1):19–25. doi:10.1007/s11934-012-0293-6 CrossRefPubMed

23.

Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Bohle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF (2015) European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol. doi:10.1016/j.eururo.2015.06.044

24.

Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European Association of U (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65(4):778–792. doi:10.1016/j.eururo.2013.11.046 CrossRefPubMed

25.

Yafi FA, Kassouf W (2009) Management of patients with advanced bladder cancer following major response to systemic chemotherapy. Expert Rev Anticancer Ther 9(12):1757–1764. doi:10.1586/era.09.148 CrossRefPubMed

26.

Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Suzuki S, Nonomura K (2007) Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 52(4):1106–1113. doi:10.1016/j.eururo.2007.02.052 CrossRefPubMed

27.

Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE (2004) Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 171(1):145–148. doi:10.1097/01.ju.0000099823.60465.e6 CrossRefPubMed

28.

Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nurnberg N, Wulfing C, Greb C, Kalble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stockle M (2009) Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol 55(6):1293–1299. doi:10.1016/j.eururo.2008.11.039 CrossRefPubMed

29.

Kanzaki R, Higashiyama M, Fujiwara A, Tokunaga T, Maeda J, Okami J, Nishimura K, Kodama K (2010) Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma. Interact CardioVasc Thorac Surg 11(1):60–64. doi:10.1510/icvts.2010.236687 CrossRefPubMed

30.

Otto T, Krege S, Suhr J, Rubben H (2001) Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Urology 57(1):55–59CrossRefPubMed

31.

Gallagher HJ, Redmond HP, Deasy J, McLean PA (1998) Hepatic resection of solitary metastasis from transitional cell carcinoma of the bladder. J Urol 159(3):986CrossRefPubMed

32.

Kim T, Ahn JH, You D, Jeong IG, Hong B, Hong JH, Ahn H, Lee JL (2015) Pulmonary metastasectomy could prolong overall survival in select cases of metastatic urinary tract cancer. Clin Genitourin Cancer 13(4):e297–e304. doi:10.1016/j.clgc.2015.04.013 CrossRefPubMed

33.

Zigouris A, Pahatouridis D, Mihos E, Alexiou GA, Nesseris J, Zikou AK, Argyropoulou MI, Goussia A, Voulgaris S (2009) Solitary cystic cerebral metastasis from transitional cell carcinoma of the bladder. Acta Neurol Belg 109(4):322–325PubMed

34.

Vaa B, Kohli M, Price KA, Swetz KM (2014) Solitary cystic cerebellar metastasis in a patient with invasive transitional cell carcinoma of the bladder. BMJ Case Reports. doi:10.1136/bcr-2013-200137 PubMed

35.

Protzel C, Zimmermann U, Asse E, Kallwellis G, Klebingat KJ (2002) Gemcitabine and radiotherapy in the treatment of brain metastases from transitional cell carcinoma of the bladder: a case report. J Neurooncol 57(2):141–145CrossRefPubMed

36.

Shamdas GJ, McLaren GD, Grimm T, Everson LK (1992) Solitary cerebellar metastasis from transitional cell carcinoma of bladder. Urology 40(1):50–53CrossRefPubMed

37.

Nonomura N, Nagahara A, Oka D, Mukai M, Nakai Y, Nakayama M, Nishimura K, Kakimoto K, Nakamura T, Usami M, Okuyama A, Miki T (2009) Brain metastases from testicular germ cell tumors: a retrospective analysis. Int J Urol 16(11):887–893. doi:10.1111/j.1442-2042.2009.02391.x CrossRefPubMed

38.

Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, European Association of U (2011) EAU guidelines on testicular cancer: 2011 update. Eur Urol 60(2):304–319. doi:10.1016/j.eururo.2011.05.038 CrossRefPubMed

39.

Copson E, McKendrick J, Hennessey N, Tung K, Mead GZ (2004) Liver metastases in germ cell cancer: defining a role for surgery after chemotherapy. BJU Int 94(4):552–558. doi:10.1111/j.1464-410X.2004.04999.x CrossRefPubMed

40.

Heidenreich A (2007) Residual tumour resection following inductive chemotherapy in advanced testicular cancer. Eur Urol 51(2):299–301. doi:10.1016/j.eururo.2006.06.046 CrossRefPubMed

41.

International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15(2):594–603

42.

Salvati M, Piccirilli M, Raco A, Santoro A, Frati R, Lenzi J, Lanzetta G, Agrillo A, Frati A (2006) Brain metastasis from non-seminomatous germ cell tumors of the testis: indications for aggressive treatment. Neurosurg Rev 29(2):130–137. doi:10.1007/s10143-005-0004-6 CrossRefPubMed

43.

Bindal RK, Sawaya R, Leavens ME, Lee JJ (1993) Surgical treatment of multiple brain metastases. J Neurosurg 79(2):210–216. doi:10.3171/jns.1993.79.2.0210 CrossRefPubMed

44.

Iwadate Y, Namba H, Yamaura A (2000) Significance of surgical resection for the treatment of multiple brain metastases. Anticancer Res 20(1B):573–577PubMed

45.

Mahalati K, Bilen CY, Ozen H, Aki FT, Kendi S (1999) The management of brain metastasis in nonseminomatous germ cell tumours. BJU Int 83(4):457–461CrossRefPubMed

46.

Rees GM, Cleland WP (1971) Surgical treatment of pulmonary metastases from testicular tumours. Br Med J 3(5772):467–470CrossRefPubMedPubMedCentral

47.

Reed RR, Barry JM, Hodges CV (1976) Testis tumor metastatic to lung: twenty-two-year survivor. Urology 7(3):302–304CrossRefPubMed

48.

Michael H, Lucia J, Foster RS, Ulbright TM (2000) The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol 24(2):257–273CrossRefPubMed

49.

Hahn TL, Jacobson L, Einhorn LH, Foster R, Goulet RJ Jr (1999) Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol 6(7):640–644CrossRefPubMed

50.

You YN, Leibovitch BC, Que FG (2009) Hepatic metastasectomy for testicular germ cell tumors: is it worth it? J Gastrointest Surg 13(4):595–601. doi:10.1007/s11605-009-0807-9 CrossRefPubMed

51.

Fitzgerald TL, Brinkley J, Banks S, Vohra N, Englert ZP, Zervos EE (2014) The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review. Langenbeck’s Arch Surg 399(8):989–1000. doi:10.1007/s00423-014-1241-3 CrossRef

52.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of U (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124–137. doi:10.1016/j.eururo.2013.09.046 CrossRefPubMed

53.

Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M (2015) Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol 68(2):325–334. doi:10.1016/j.eururo.2014.07.020 CrossRefPubMed

54.

Hatzoglou V, Patel GV, Morris MJ, Curtis K, Zhang Z, Shi W, Huse J, Rosenblum M, Holodny AI, Young RJ (2014) Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. J Neuroimagin 24(2):161–166. doi:10.1111/j.1552-6569.2012.00767.x CrossRef

55.

Castro Gomez JE, Anido Herranz U, Carballo Castro A, Gomez Caamaoo A, Leon Mateos LA, Porto Vazquez C, Lopez Lopez R (2009) Brain metastases from prostate adenocarcinoma. Clin Trans Oncol 11(1):63–64CrossRef

56.

Wallis CJ, English JC, Goldenberg SL (2011) The role of resection of pulmonary metastases from prostate cancer: a case report and literature review. Can Urol Assoc J 5(6):E104–E108. doi:10.5489/cuaj.10136 CrossRefPubMedPubMedCentral

57.

Ratasvuori M, Wedin R, Hansen BH, Keller J, Trovik C, Zaikova O, Bergh P, Kalen A, Laitinen M (2014) Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases. J Surg Oncol 110(4):360–365. doi:10.1002/jso.23654 CrossRefPubMed

58.

Weiss RJ, Forsberg JA, Wedin R (2012) Surgery of skeletal metastases in 306 patients with prostate cancer. Acta orthopaedica 83(1):74–79. doi:10.3109/17453674.2011.645197 CrossRefPubMedPubMedCentral

59.

Hakenberg OW, Comperat EM, Minhas S, Necchi A, Protzel C, Watkin N, Association E, European Association of U (2015) EAU guidelines on penile cancer: 2014 update. Eur Urol 67(1):142–150. doi:10.1016/j.eururo.2014.10.017 CrossRefPubMed

60.

Djajadiningrat RS, van Werkhoven E, Horenblas S (2015) Prophylactic pelvic lymph node dissection in patients with penile cancer. J Urol 193(6):1976–1980. doi:10.1016/j.juro.2014.12.019 CrossRefPubMed

61.

Chalya PL, Rambau PF, Masalu N, Simbila S (2015) Ten-year surgical experiences with penile cancer at a tertiary care hospital in northwestern Tanzania: a retrospective study of 236 patients. World J Surg Oncol 13:71. doi:10.1186/s12957-015-0482-0 CrossRefPubMedPubMedCentral

62.

Pettaway CA, Pagliaro L, Theodore C, Haas G (2010) Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 76(2 Suppl 1):S58–S65. doi:10.1016/j.urology.2010.03.082 CrossRefPubMed

Titel: Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?
verfasst von: Senol Tonyali
Sertac Yazici
Publikationsdatum: 03.02.2016
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 5/2016
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-016-1226-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Inhibiting malignant phenotypes of the bladder cancer cells by silencing long noncoding RNA SChLAP1

Predicting technique and patient survival over 12 months in peritoneal dialysis: the role of anxiety and depression

Expression and prognostic significance of ELL-associated factor 2 in human prostate cancer

Erratum to: Predicting technique and patient survival over 12 months in peritoneal dialysis: the role of anxiety and depression

Oncological outcomes and prognostic factors after nephron-sparing surgery in renal cell carcinoma